丹纳赫宣布诊断开发与商业化合作,扩大精准医疗规模

动脉网
30 May

丹纳赫公司已与 阿斯利康 合作,通过开发和商业化新型诊断工具和测试来推动 精准医疗 的发展。该合作旨在建立一个快速诊断研究、开发和商业化的框架,利用丹纳赫的精准医疗赋能中心支持整个开发过程。通过此次合作开发的首个产品将利用丹纳赫子公司徕卡生物系统的技术,初期重点聚焦于数字与计算病理学。此次合作旨在提高精准药物的可及性,并确保最能从中受益的患者不会被遗漏。(摘要由动脉网AI生成)

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10